KENNESAW, Ga., Dec. 28, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company's $5,000,000 private placement offering to sell convertible notes and warrants has been fully subscribed.
Through the offering, which commenced on October 15, 2011, the Company received $5,000,000 in proceeds and issued 5% Convertible Senior Secured Promissory Notes that are convertible into approximately 5,000,000 shares of common stock at a price of $1.00 per share. Participating investors also received contingent warrants to purchase the Company's common stock. More details regarding the private placement, including the terms of the warrants, are disclosed in the Company's SEC filings.
Parker H. "Pete" Petit, Chairman and CEO, said, "We are pleased with the receptivity to this offering and especially gratified by the speed at which investors acted upon this opportunity. We are excited that they share the same level of enthusiasm regarding the market potential of our products and tissues. We appreciate the confidence of the new investors that participated in this private placement. As with our previous private placements, I again personally participated in this offering. This capital should provide the Company with sufficient cash to transition beyond EBITDA breakeven and profitability and afford MiMedx with funds to accelerate our revenue growth."
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the d
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved